Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 12,805 | 1,377 | 11,296 |
| Samples | 1,224 | 218 | 988 |
| Peptides | 1,080 | 168 | 928 |
Function
FN1 · Fibronectin 1
This gene encodes fibronectin, a glycoprotein present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix. The encoded preproprotein is proteolytically processed to generate the mature protein. Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis. The gene has three regions subject to alternative splicing, with the potential to produce 20 different transcript variants, at least one of which encodes an isoform that undergoes proteolytic processing. The full-length nature of some variants has not been determined. [provided by RefSeq, Jan 2016].
Isoforms & Proteins
11 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000354785 | P02751 | 1,457 | 1,042 |
| ENST00000323926 | P02751-7 | 1,305 | 980 |
| ENST00000359671 | P02751-1 | 1,257 | 947 |
| ENST00000336916 | P02751-3 | 1,247 | 937 |
| ENST00000446046 | P02751-17 | 1,237 | 929 |
| ENST00000432072 | P02751-13 | 1,203 | 903 |
| ENST00000356005 | P02751-8 | 1,200 | 906 |
| ENST00000443816 | P02751-14 | 1,190 | 896 |
| ENST00000421182 | P02751-9 | 1,187 | 894 |
| ENST00000357867 | P02751-10 | 1,145 | 860 |
| ENST00000426059 | P02751-16 | 377 | 277 |
Gene Properties
Recurrent Mutations
All 1042 amino-acid changes on canonical ENST00000354785 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FN1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FN1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 53/612 9% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 51/810 6% |
| Melanoma | 19/210 9% | 105/1899 6% |
| Hodgkins Lymphoma | 4/16 25% | 4/122 3% |
| Colorectal Carcinoma | 37/143 26% | 157/3239 5% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Other Solid Cancers | 8/94 9% | 72/1515 5% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Gastric Carcinoma | 5/74 7% | 71/1809 4% |
| Neuroendocrine Tumour | 15/154 10% | 12/577 2% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 41/1390 3% |
| Plasma Cell Myeloma | 6/44 14% | 5/305 2% |
| Cervical Carcinoma | 1/35 3% | 13/422 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Bladder Carcinoma | 3/58 5% | 28/956 3% |
| Esophageal Carcinoma | 0/23 0% | 24/769 3% |
| Small Cell Lung Carcinoma | 1/9 11% | 19/752 3% |
| Adrenocortical Carcinoma | 0/3 0% | 3/112 3% |
| Head and Neck Carcinoma | 5/85 6% | 36/1574 2% |
| Non-Cancerous | 7/104 7% | 15/830 2% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 46/2550 2% |
| Ovarian Carcinoma | 11/109 10% | 10/998 1% |
| Hepatocellular Carcinoma | 1/46 2% | 38/2210 2% |
| Other Sarcomas | 2/69 3% | 10/699 1% |
| Pancreatic Carcinoma | 8/89 9% | 17/1611 1% |
Mutation Distribution
Where FN1 is mutated · all tissues, split by cell line vs tissue
How many mutations in FN1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 12,805 mutations in FN1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|